Phase 12 Study Evaluating BMS-986458 Alone and With Other Anti-Lymphoma Drugs in Adults with Relapsed or Refractory Non-Hodgkin Lymphoma

What this Trial Is About

This research focuses on adults with relapsed or refractory Non-Hodgkin Lymphoma NHL. It aims to study the safety, tolerability, drug levels, and early biological and clinical effects of BMS-986458, a specialized drug designed to target B-cell lymphoma 6 BCL6. The study evaluates BMS-986458 both alone and combined with other anti-lymphoma treatments to better understand its potential in managing NHL. Participants may receive BMS-986458 alone or in combination with drugs like Rituximab, GlofitamabObinutuzumab, Mosunetuzumab, Epcoritamab, or Golcadomide. Dosing occurs on specified days tailored to each treatment group. The study is divided into multiple parts, including single-agent and combination treatment groups, all actively monitored for response and safety. During the trial, participants will have regular assessments for adverse events, drug levels, and treatment responses using criteria like the Lugano response. The study includes monitoring up to three years for outcomes such as overall survival and progression-free survival. Participants will undergo scans, laboratory tests, and clinical evaluations throughout the study to measure treatment effects and safety over time.

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas